Your browser doesn't support javascript.
loading
Inhibition of c-MYC-miRNA 19 Pathway Sensitized CML K562 Cells to Etoposide via NHE1 Upregulation.
Cao, Shannan; Xiong, Qingqing; Ding, Bowen; Wang, Xu; Wei, Feng; Sun, Qian; Yang, Fan; Luo, Jing; Chang, Guoqiang; Li, Suxin; Wang, Jian.
Afiliación
  • Cao S; Clinical Laboratory, Yantai Affiliated Hospital of Binzhou Medical University, Yantai 264000, China.
  • Xiong Q; Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
  • Ding B; Department of Breast Reconstruction, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China.
  • Wang X; Department of Pharmacology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, Texas 75390, USA.
  • Wei F; Department of Immunology, Department of Biotherapy, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin Medical University Cancer Institute & Hosp
  • Sun Q; Department of Immunology, Department of Biotherapy, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin Medical University Cancer Institute & Hosp
  • Yang F; Department of Immunology, Department of Biotherapy, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin Medical University Cancer Institute & Hosp
  • Luo J; Department of Immunology, Department of Biotherapy, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin Medical University Cancer Institute & Hosp
  • Chang G; Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin 300052, China.
  • Li S; Department of Pharmaceutics, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China.
  • Wang J; Department of Immunology, Department of Biotherapy, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin Medical University Cancer Institute & Hosp
Oxid Med Cell Longev ; 2022: 9306614, 2022.
Article en En | MEDLINE | ID: mdl-35915613
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Neoplasias Hematológicas / MicroARNs / Intercambiador 1 de Sodio-Hidrógeno Límite: Animals / Humans Idioma: En Revista: Oxid Med Cell Longev Asunto de la revista: METABOLISMO Año: 2022 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Neoplasias Hematológicas / MicroARNs / Intercambiador 1 de Sodio-Hidrógeno Límite: Animals / Humans Idioma: En Revista: Oxid Med Cell Longev Asunto de la revista: METABOLISMO Año: 2022 Tipo del documento: Article País de afiliación: China